Inovio says Ebola vaccine provides 100% protection in preclinical study
Inovio Pharmaceuticals announced that its Ebola vaccine INO-4212 provided 100% protection following a challenge with a lethal dose of the Ebola virus in a preclinical study. An article in the Journal of Infectious Diseases highlights that regimens of Inovio's INO-4212 vaccine delivered by intramuscular administration provided 100% protection against a lethal Ebola challenge in all preclinical subjects. Impressively, just two injections of a simple, dose-sparing intradermal administration generated strong immunogenicity and provided 100% protection against a lethal Ebola challenge in a separate study. Scientists observed that vaccination induced long-term immune responses in monkeys that were detectable for at least one year after the final vaccination. In a completed Phase 1 Ebola trial of healthy participants demonstrated that 95% of evaluable subjects generated an Ebola-specific antibody immune response, with the mean antibody titer comparable or superior to those reported from viral vector-based Ebola vaccines. Importantly, Inovio's Ebola vaccine was well-tolerated with a favorable safety profile compared to viral vector-based Ebola vaccines, some of which have been associated with serious adverse events including myalgia, arthralgia, fever, and rash. Furthermore, their faster construct design, ability to continue to boost immune responses and protection with additional administrations, easier scalability of manufacturing, and better product thermal stability make DNA vaccines an attractive platform to rapidly respond to emerging global infectious diseases. Laurent Humeau, Ph.D., Inovio's Senior Vice President R&D, said, "Unlike all other Ebola vaccine candidates in development, INO-4212 is a vaccine that has shown to be stable at room temperature for one year. With this new data showing complete Ebola protection, coupled with impressive Phase 1 results for immune responses and safety, Inovio is well-positioned to execute on our overall development strategy in positioning INO-4212 as a viable stockpile vaccine. We are working with collaborators and potential new funders to advance INO-4212."